Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.9B | $27.4B | $30.6B | $31.9B | $34.6B | $43.1B | $43.7B | $40.1B | $42.0B | $44.3B |
| Revenue growth | — | 31.3% | 11.6% | 4.3% | 8.5% | 24.5% | 1.3% | -8.1% | 4.6% | 5.7% |
| Operating income | $3.03B | $1.56B | $3.65B | $4.53B | $5.36B | $8.43B | $8.36B | $6.48B | $6.83B | $8.05B |
| Operating margin | 14.5% | 5.7% | 11.9% | 14.2% | 15.5% | 19.6% | 19.2% | 16.2% | 16.3% | 18.2% |
| Net income | $1.40B | $477M | $2.37B | $3.69B | $4.50B | $7.07B | $6.93B | $5.72B | $13.4B | $6.52B |
| Net margin | 6.7% | 1.7% | 7.7% | 11.6% | 13.0% | 16.4% | 15.9% | 14.3% | 31.9% | 14.7% |
| EPS (diluted) | $0.94 | $0.27 | $1.33 | $2.06 | $2.50 | $3.94 | $3.91 | $3.26 | $7.64 | $3.72 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.20B | $5.57B | $6.30B | $6.14B | $7.90B | $10.5B | $9.58B | $7.26B | $8.56B | $9.57B |
| Capital expenditures | $1.12B | $1.14B | $1.39B | $1.64B | $2.18B | $1.89B | $1.78B | $2.20B | $2.21B | $2.17B |
| Free cash flow | $2.08B | $4.43B | $4.91B | $4.50B | $5.72B | $8.65B | $7.80B | $5.06B | $6.35B | $7.39B |
| Share buybacks | $522M | $117M | $238M | $718M | $403M | $2.30B | $3.79B | $1.23B | $1.29B | $893M |
| Dividends paid | $1.54B | $1.85B | $1.97B | $2.27B | $2.56B | $3.20B | $3.31B | $3.56B | $3.84B | $4.12B |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $18.6B | $9.41B | $3.84B | $3.86B | $6.84B | $9.80B | $9.88B | $6.90B | $7.62B | $8.52B |
| Total assets | $52.7B | $76.3B | $67.2B | $67.9B | $72.5B | $75.2B | $74.4B | $73.2B | $81.4B | $86.7B |
| Long-term debt | $20.7B | $27.2B | $19.4B | $16.7B | $18.5B | $17.3B | $14.5B | $13.6B | $12.6B | $9.90B |
| Shareholders' equity | $20.5B | $30.9B | $30.5B | $31.1B | $32.8B | $35.8B | $36.7B | $38.6B | $47.7B | $52.1B |
| Retained earnings | $25.6B | $24.0B | $24.6B | $25.8B | $27.6B | $31.5B | $35.3B | $37.6B | $47.3B | $49.8B |
| Shares (wtd avg diluted) | 1.48B | 1.75B | 1.77B | 1.78B | 1.79B | 1.79B | 1.76B | 1.75B | 1.75B | 1.75B |
Every figure is extracted from ABBOTT LABORATORIES’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.